Strategies of reducing input sample volume for extracting circulating cell-free nuclear DNA and mitochondrial DNA in plasma

Chen, Weijie; Cai, Fengfeng; Zhang, Bei; Zhong, Xiao Yan

doi:10.1515/cclm.2011.773

Cited by 7 publications

(4 citation statements)

References 20 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Automated extraction is available and should henceforth be preferred [43] . Extracted material is usually well-suited for polymerase chain reaction (PCR), sequencing faces to DNA breaks and other DNA modifications [44] .…”

Section: Preanalytical Phase For Molecular Biology Testingmentioning

confidence: 99%

Preanalytical quality improvement: in quality we trust

Lippi

Becan-McBride

Behúlová

et al. 2012

Clinical Chemistry and Laboratory Medicine (CCLM)

189

123

View full text Add to dashboard Cite

Total quality in laboratory medicine should be defined as the guarantee that each activity throughout the total testing process is correctly performed, providing valuable medical decision-making and effective patient care. In the past decades, a 10-fold reduction in the analytical error rate has been achieved thanks to improvements in both reliability and standardization of analytical techniques, reagents, and instrumentation. Notable advances in information technology, quality control and quality assurance methods have also assured a valuable contribution for reducing diagnostic errors. Nevertheless, several lines of evidence still suggest that most errors in laboratory diagnostics fall outside the analytical phase, and the pre-and postanalytical steps have been found to be much more vulnerable. This collective paper, which is the logical continuum of the former already published in this journal 2 years ago, provides additional contribution to risk management in the preanalytical phase and is a synopsis of the lectures of the 2nd European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)-Becton Dickinson (BD) European Conference on Preanalytical Phase meeting entitled " Preanalytical quality improvement: in quality we trust " (Zagreb, Croatia, 1 -2 March 2013). The leading topics that will be discussed include quality indicators for preanalytical phase, phlebotomy practices for collection of blood gas analysis and pediatric samples, lipemia and blood collection tube interferences, preanalytical requirements of urinalysis, molecular biology hemostasis and platelet testing, as well as indications on best practices for safe blood collection. Auditing of the preanalytical phase by ISO assessors and external quality assessment for preanalytical phase are also discussed.

show abstract

Section: Preanalytical Phase For Molecular Biology Testingmentioning

confidence: 99%

Preanalytical quality improvement: in quality we trust

Lippi

Becan-McBride

Behúlová

et al. 2012

Clinical Chemistry and Laboratory Medicine (CCLM)

189

123

View full text Add to dashboard Cite

show abstract

“…We designed the C-MYC gene sequence for forward primer: 5 -TCAAGAGGCGAACACACAAC-3 ; reverse primer: 5 -TAACTACCTTGGGGGCCTTT-3 . We also designed the GAPDH gene [24,25] sequence as the housekeeping gene for forward primer: 5 -CTCTGCTCCTCCTGTTCGAC-3 ; reverse primer: 5 -ACGACCAAATCCGTTGACTC-3 . The primer was synthesized by Sangon Biotech, Inc. (Shanghai, China).…”

Section: Quantitative Real Time Pcr Assaymentioning

confidence: 99%

Plasma C-MYC Level Manifesting As An Indicator in Progression of Breast Cancer

Shi

Huang

et al. 2019

Biomark. Med.

View full text Add to dashboard Cite

Aim: To investigate whether plasma C-MYC level could be an indicator in clinical progression of breast cancer. Materials & methods: Plasma level of C-MYC expression was detected by quantitative real time PCR and the level of c-myc protein in breast cancer tissues was detected by immunohistochemistry. The expression level of C-MYC mRNA in supernatant of cancer cells culture was measured compared with the nonbreast cancer cells. Results: Plasma C-MYC level was significantly higher in patients with breast cancer than that in the controls, which associated with clinical stages, lymph node status, etc. Receiver operating characteristic curve analysis showed the sensitivity and specificity of plasma C-MYC level for diagnosis of breast cancer were 63.6 and 81.8%, respectively. The expression of c-myc protein in breast cancer tissues was associated with plasma C-MYC level, even C-MYC level in supernatant of cancer cells was elevated. Conclusion: Plasma C-MYC level might be a potential indicator in progression of breast cancer.

show abstract

“…Three L of DNA elution were used as a template for the Sybr-green based real time PCR analysis. The amount of cell free DNA was quantified using a pair of primers as previously described [26]. The cell free DNA concentration was calculated according to a reproducible standard dilution curves using a known concentration of MCF-7 genomic DNA.…”

Section: Sample Collection and Isolation Of Cell Free Dnamentioning

confidence: 99%